Published December 2020
| Version v1
Journal article
Fluropyrimidine single agent or doublet chemotherapy as second line treatment in advanced biliary tract cancer
Creators
- Neuzillet, Cindy
- Casadei‐gardini, Andrea
- Brieau, Bertrand
- Vivaldi, Caterina
- Brandi, Giovanni
- Tougeron, David
- Filippi, Roberto
- Vienot, Angélique
- Silvestris, Nicola
- Pointet, Anne‐laure
- Lonardi, Sara
- Rousseau, Benoît
- Scartozzi, Mario
- Dahan, Laetitia
- Aprile, Giuseppe
- Sourd, Samuel Le
- Evesque, Ludovic
- Meurisse, Aurélia
- Lièvre, Astrid
- Vernerey, Dewi
Contributors
Others:
- Institut Curie [Paris]
- Université de Versailles Saint-Quentin-en-Yvelines - UFR Sciences de la santé Simone Veil (UVSQ Santé) ; Université de Versailles Saint-Quentin-en-Yvelines (UVSQ)
- Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE)
- Hôpital Cochin [AP-HP] ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)
- University of Pisa - Università di Pisa
- Policlinico S. Orsola-malpighi ; Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO)-Servizio sanitario regionale Emilia-Romagna
- Centre hospitalier universitaire de Poitiers (CHU Poitiers)
- Università degli studi di Torino = University of Turin (UNITO)
- Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)
- Università degli studi di Bari Aldo Moro = University of Bari Aldo Moro (UNIBA)
- Hôpital Européen Georges Pompidou [APHP] (HEGP) ; Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpitaux Universitaires Paris Ouest - Hôpitaux Universitaires Île de France Ouest (HUPO)
- Istituti di Ricovero e Cura a Carattere Scientifico (IRCCS)
- CHU Henri Mondor
- Università degli Studi di Cagliari = University of Cagliari (UniCa)
- Hôpital de la Timone [CHU - APHM] (TIMONE)
- Università degli Studi di Udine - University of Udine [Italie]
- CRLCC Eugène Marquis (CRLCC)
- Centre de Lutte contre le Cancer Antoine Lacassagne [Nice] (UNICANCER/CAL) ; UNICANCER-Université Côte d'Azur (UCA)
- Chemistry, Oncogenesis, Stress and Signaling (COSS) ; Université de Rennes 1 (UR1) ; Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-CRLCC Eugène Marquis (CRLCC)-Institut National de la Santé et de la Recherche Médicale (INSERM)
Description
Fluoropyrimidine (FP) plus platinum chemotherapy has been recently established as a second-line (L2) preferred option in advanced biliary tract cancer (aBTC) (ABC-06 phase III trial). However, the overall survival (OS) benefit was limited and comparison with FP monotherapy was not available. Our aim was to assess the OS of patients treated with a FP monotherapy compared to a doublet with irinotecan or platinum in L2. We performed a retrospective analysis of two large multicenter prospective cohorts: a French cohort (28 centers) and an Italian cohort (9 centers). All consecutive patients with aBTC receiving FP-based L2 after gemcitabine plus cisplatin/gemcitabine plus oxaliplatin L1 between 2003 and 2016 were included. A subgroup analysis according to performance status (PS) and an exploratory analysis according to platinum sensitivity in L1 were planned. In the French cohort (n = 351), no significant OS difference was observed between the FP monotherapy and doublet groups (median OS: 5.6 vs 6.8 months, P = .65). Stratification on Eastern Cooperative Oncology Group (ECOG) PS showed similar results in PS 0-1 and 2. Median OS was not different between FP monotherapy, platinum- and irinotecan-based doublets (5.6 vs 7.1 vs 6.7 months, P = .68). Similar findings were observed in the Italian cohort (n = 174) and in the sensitivity analysis in pooled cohorts (n = 525). No L2 regimen seemed superior over others in the platinum resistant/refractory or sensitive subgroups. Our results suggest that FP monotherapy is as active as FP doublets in aBTC in L2, regardless of the patient PS and country, and could be a therapeutic option in this setting.
Abstract
International audienceAdditional details
Identifiers
- URL
- https://hal-univ-rennes1.archives-ouvertes.fr/hal-02929354
- URN
- urn:oai:HAL:hal-02929354v1
Origin repository
- Origin repository
- UNICA